Septerna (NASDAQ:SEPN) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Septerna (NASDAQ:SEPN) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $40.00 price target on the stock.

Several other analysts also recently issued reports on SEPN. Wall Street Zen downgraded shares of Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Thursday, January 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $60.00 price objective on shares of Septerna in a report on Tuesday, March 10th. Truist Financial upped their price objective on shares of Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Finally, JonesTrading initiated coverage on shares of Septerna in a report on Tuesday, December 23rd. They set a “buy” rating and a $43.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Septerna presently has an average rating of “Moderate Buy” and an average price target of $43.14.

Septerna Stock Up 3.4%

SEPN stock opened at $24.13 on Tuesday. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -21.74 and a beta of 3.50. Septerna has a 12 month low of $5.73 and a 12 month high of $32.63. The firm has a 50 day moving average of $26.15 and a two-hundred day moving average of $25.03.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, March 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.01). Septerna had a negative return on equity of 15.85% and a negative net margin of 106.37%. On average, research analysts expect that Septerna will post -7.11 EPS for the current fiscal year.

Insider Buying and Selling at Septerna

In other Septerna news, insider Samira Shaikhly sold 70,453 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $28.10, for a total value of $1,979,729.30. Following the completion of the sale, the insider directly owned 793 shares of the company’s stock, valued at $22,283.30. This represents a 98.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total transaction of $115,880.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $5,046,834.73. This trade represents a 2.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Septerna

A number of hedge funds have recently bought and sold shares of SEPN. Woodline Partners LP boosted its holdings in Septerna by 94.2% in the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after purchasing an additional 282,585 shares during the period. Rhumbline Advisers boosted its holdings in Septerna by 16.6% in the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock valued at $135,000 after purchasing an additional 3,323 shares during the period. Geode Capital Management LLC boosted its holdings in Septerna by 19.1% in the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock valued at $5,158,000 after purchasing an additional 78,316 shares during the period. JPMorgan Chase & Co. boosted its holdings in Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after purchasing an additional 1,315 shares during the period. Finally, CW Advisors LLC bought a new stake in Septerna in the 2nd quarter valued at $133,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.